Early Daraxonrasib Combination Results Show Pancreatic Tumor Responses
A Phase 1/2 study of daraxonrasib plus chemotherapy in 61 patients reported disease control in about 90%, tumor shrinkage or disappearance in just over 60%, and no detectable tumor on scans in roughly 8%; coverage also reports one-year survival of 76.6%. The uncontrolled early data do not establish cure or survival benefit; randomized results, durability, and safety are needed.
Sources (3)
Updated Nov 20, 2026